NCT03790891Unknown早期 1 期
Adoptive Immunotherapy for Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell
Timmune Biotech Inc.3 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2019年1月5日最近更新:
适应症
试验速览
- 阶段
- 早期 1 期
- 发起方
- 入组人数
- 12
- 试验地点
- 3
- 主要终点
- safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）
研究概览
简要总结
This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Non-Hodgkin lymphoma treatment.
详细描述
CD19-TriCAR contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the CD19-TriCAR-T/SILK to simultaneously targeting the CD19 positive Non-Hodgkin lymphoma，blocking the inhibitory PD-L1 signal and stimulating innate T/NK cell activation and expansion, thus make it a tri-functional CAR (Tri-CAR). CD19-TriCAR-T is an autologous tri-functional CAR-T cell therapy, CD19-TriCAR-SILK is an Allogeneic tri-functional CAR-NK cell therapy, patients ineligible for leukapheresis or CAR-T therapy will be recommended for CD19-TriCAR-SILK therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects must personally sign and date the consent form before initiating any study specific procedures or activities;
- •All subjects must be able to comply with all the scheduled procedures in the study;
- •Refractory or relapsed malignant Non-Hodgkin lymphoma, defined as one or more of the following: Relapsed in 6 months after most recent therapy; Progressive disease in standard chemotherapy; Disease progression or relapsed in ≤12 months of ASCT;
- •At least one measurable lesion per revised IWG Response Criteria;
- •Aged <70 years;
- •Expected survival ≥12 weeks; Eastern cooperative oncology group (ECOG) performance status of≤2;
- •Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks;
- •All other treatment induced adverse events must have been resolved to ≤grade 1;
- •Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB>70g/L, Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN, Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);
排除标准
- •Presence of fungal, bacterial, viral, or other infection that is hardly to control（defined by investigator）;
- •Patients with symptomatic central nervous system metastasis, intracranial metastasis, and cancer cells found in cerebrospinal fluid are not recommended to participate in this study. Symptom free or post-treatment stable disease or disappearance of lesions should not be excluded. The specific selection is ultimately determined by the investigator;
- •Lactating women or women of childbearing age who plan to conceive during the time period;
- •Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV positive);
- •Known history of infection with HIV;
- •Subjects need systematic usage of corticosteroid;
- •Subjects need systematic usage of immunosuppressive drug;
- •Planed operation, history of other related disease, or any other related laboratory tests restrict patients for the study;
- •Other reasons the investigator consider the patient may not be suitable for the study.
结局指标
主要结局
safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）
时间窗: 24 months
Incidence of treatment-related adverse events as assessed by CTCAE v4.03
次要结局
- Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)(24 months)
- Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）(24 months)
- Duration of Response （The time from response to relapse or progression）(24 months)
- Progression Free Survival （The time from the first day of treatment to the date on which disease progresses）(24 months)
- Overall Survival （The number of patient alive, with or without signs of cancer）(24 months)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
早期 1 期
Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyNon-Hodgkin Lymphoma of IntestineLeukemiaNCT03910842Timmune Biotech Inc.12
Unknown
1 期
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell TherapyNon-hodgkin Lymphoma,B CellNCT03720496Timmune Biotech Inc.6
Unknown
1 期
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19Non-hodgkin Lymphoma,B CellNCT03497533Timmune Biotech Inc.6
Unknown
1 期
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaNCT04012879Chinese PLA General Hospital12
Unknown
1 期
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNCT04012892Chinese PLA General Hospital12